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Background: To detect genetic expression profile alterations after papillary thyroid carcinoma (PTC) cells
transfected with chemokine receptor CXCR7 gene by gene microarray, and gain insights into molecular
mechanisms of how CXCR7 regulating PTC growth and metastasis.
Methods: The Human OneArray microarray was used for a complete genome-wide transcript profiling of CXCR7
transfected PTCs (K1-CXCR7 cells), defined as experimental group. Non CXCR7 transfected PTCs (K1 cells) were used
as control group. Differential analysis for per gene was performed with a random variance model and t test, p
values were adjusted to control the false discovery rate. Gene ontology (GO) on differentially expressed genes to
identify the biological processes in modulating the progression of papillary thyroid carcinoma. Pathway analysis
was used to evaluate the signaling pathway that differentially expressed genes were involved in. In addition,
quantitative real-time polymerase chain reaction (q-PCR) and Western blot were used to verify the top differentially
expression genes.
Results: Comparative analysis revealed that the expression level of 1149 genes was changed in response to CXCR7
transfection. After unsupervised hierarchical clustering analysis, 270 differentially expressed genes were filtered, of
them 156 genes were up-regulated whereas 114 genes were down-regulated in K1-CXCR7 cells. GO enrichment
analysis revealed the differentially expressed genes were mainly involved in biopolymer metabolic process, signal
transduction and protein metabolism. Pathway enrichment analysis revealed differentially expressed genes were
mainly involved in ECM-receptor interaction, Focal adhesion, MAPK signaling pathway and Cytokine-cytokine
receptor interaction pathway. More importantly, the expression level of genes closely associated with tumor growth
and metastasis was altered significantly in K1-CXCR7 cells, including up-regulated genes FN1, COL1A1, COL4A1,
PDGFRB, LTB, CXCL12, MMP-11, MT1-MMP and down-regulated genes ITGA7, and Notch-1.
Conclusions: Gene expression profiling analysis of papillary thyroid carcinoma can further delineate the
mechanistic insights on how CXCR7 regulating papillary thyroid carcinoma growth and metastasis. CXCR7 may
regulate growth and metastasis of papillary thyroid carcinoma via the activation of PI3K/AKT pathway and its
downstream NF-κB signaling, as well as the down-regulation of Notch signaling.
Keywords: Thyroid carcinoma, Chemokine receptor, CXCR7, Invasion, Metastasis, Gene microarray, Signal pathway* Correspondence: liuz@sj-hospital.org
†Equal contributors
Department General Surgery, Affiliated Shenjing Hospital, China Medical
University, No.36 Sanhao Street, Shenyang 110004, China
© 2015 Zhang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Table 1 Primers used in this study
Genes Primers Length
(bp)
FN1 Forward:5′- GAGTGTGTGTGTCTTGGTAATGG-3′ 108
Reverse:5′- CCACGTTTCTCCGACCAC-3′
COL1A1 Forward:5′- CCTGGATGCCATCAAAGTCT-3′ 153
Reverse:5′-AATCCATCGGTCATGCTCTC-3′
COL4A1 Forward:5′- CTGGTCCAAGAGGATTTCCA-3′ 193
Reverse:5′-TCATTGCCTTGCACGTAGAG-3′




CXCL12 Forward:5′- CCATGCCGATTCTTCGAAAG-3′ 101
Reverse:5′- TTCAGCCGGGCTACAATCTG-3′








GAPDH Forward:5′- GCACCGTCAAGGCTGAGAAC-3′ 138
Reverse:5′-TGGTGAAGACGCCAGTGGA-3′
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Thyroid carcinoma is the most common endocrine
neoplasm, and its incidence has been explosively rising
worldwide over the past few decades. Papillary thyroid
carcinoma is the most common pathological type of
thyroid carcinoma, accounting for at least 70–80% of
thyroid carcinoma. Although PTC has a favorable prog-
nosis, certain cases exhibit aggressive clinical character-
istics, such as lymph node metastasis.
Chemokines and their receptors play a critical role in
tumorigenesis, progression, and metastasis of tumor [1].
The chemokine receptor CXCR7 mediates cellular ad-
hesion, migration, proliferation, and survival by bind-
ing its ligands stromal cell-derived factor-1(SDF-1) and
Interferon-inducible T cell α-chemoattractant (I-TAC)
[2,3]. In recent years, accumulating evidences had de-
monstrated that expression of CXCR7 played a critical
role in tumor cell proliferation, angiogenesis, invasion,
and metastasis [4-7]. In our previous study, we have dem-
onstrated that CXCR7 and SDF-1 were over-expressed in
PTC tissue compared with peritumoral nonmalignant tis-
sue and thyroid benign lesion tissue, and the expressions
of them were positively associated with lymph node
metastasis [8]. In addition, we found that knockdown of
CXCR7 in PTC cells suppressed cell proliferation, inva-
sion, induced S phase arrest, and promoted apoptosis [9].
To further evaluate the signaling pathways involved in
CXCR7 receptor regulated PTC progression, we used
gene microarray to detect the altered gene expression in
PTC cells transfected with CXCR7 and tried to gain in-
sights into molecular mechanisms of how CXCR7 regu-
lating PTC growth and metastasis.
Methods
Cell lines and culture conditions
The human papillary thyroid carcinoma cell line K1 was
purchased from European Collection of Animal Cell
Cultures. Stable human CXCR7 cDNA transfected cell
line, K1-CXCR7, was established in our laboratory [9].
Both cells were cultured in Dulbecco’s Modified Eagle’s
Medium: Ham’s F12:MCDB105 (Sigma-Aldrich, St. Louis,
Missouri) containing 10% fetal calf serum (FCS; Sigma-
Aldrich) and 2 mmol/L glutamine (Sigma-Aldrich). This
study was approved by the Ethics Committee in the Affili-
ated Shengjing Hospital of China Medical University.
RNA preparation and microarray analysis
The gene microarray analysis was carried out by Phalanx
Biotech Group, which included RNA amplification, label-
ing of probe, hybridization, and data extraction. Briefly,
total RNA was extracted from K1-CXCR7 cells as ex-
perimental group (O1,O2,O3) and K1 cells as control
group (N1, N2, N3) using Trizol reagent (TaKaRa Bio Inc,
Japan) according to the manufacturer’s instructions. RNAquantity and purity were assessed by using NanoDrop
ND-1000 to measure OD260/280. RNA integrity was
ascertained by using Agilent RNA 6000 Nano assay to
determine RNA Integrity Number (RIN) values. Gene
expression profiling was conducted with the Human
OneArray® V6.1 microarray (OneArray, China Taiwan)
containing 31741 human genome probes and 938 ex-
perimental control probes [10]. After hybridization,
arrays were washed, scanned and then gene expression
results were extracted by DNA Microarray Scanner
G2565B (Agilent Technologies, United States) according
to the manufacturer’s instructions. Raw fluorescence
intensity values were normalized and log-transformed
using GeneSpring GX 10 software (Agilent Technologies,
United States).Quantitative real-time polymerase chain reaction
Total RNA was extracted using Trizol reagent (TaKaRa
Bio Inc, Japan) according to the manufacturer’s instruc-
tions. Quantitative real-time polymerase chain reaction
(q-PCR) analysis was performed on Lightcycler480 (Roche
Applied Science) according to the manufacturer’s proto-
col. GAPDH was used as internal control to normalize
mRNA levels. All the experiments were repeated three
times. Primer sequences are listed in Table 1.
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:16 Page 3 of 12Western blotting
Cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and extracted according to protein extraction
protocols. Protein concentrations were determined by the
BCA Protein Assay Kit (Beyotime Biotechnology, China).
Total protein samples (80 ug/lane) were electrophoresed
on sodium dodecyl sulfate-polyacrylamide gel and then
transferred to Polyvinylidene Fluoride membrane. After
blocking with 5% non-fat dry milk for 2 h, membranes
were incubated with primary antibodies overnight at
4°C. The membranes were incubated for 2 h at room
temperature with secondary antibody. Antibodies used
in this study included the following: rabbit polyclonal
anti FN1 (1:400), anti-COL1A1 (1:200), anti-COL4A1
(1:500), anti-CXCL12 (1:400), anti-PDGFRB (1:200),
anti-MMP-11 (1:200), anti-MTI-MMP (1:200), anti-
ITGA7 (1:200, all from BOSTER, Wuhan, China), rabbit
polyclonal anti-LTB (1:500, from Abcam, Cambridge,
MA), and rabbit polyclonal anti-Notch1 (1:1000), GAPDH
(1:10000, both from Proteintech Group Inc, Chicago, IL),
and goat anti-rabbit IgG (1:2000; ZSGB-BIO, China) as sec-
ondary antibody. Binding was detected using the enhanced
chemiluminescence reagents (Beyotime Biotechnology,
China). The ratio between the integated optical density
of interest proteins and GAPDH of the same sampleFigure 1 Histograms with fold change between the experimental and
fluorescence signal intensity ratios for differentially expressed genes. And lo
The histogram plot shows fold change distribution of all probes excluding
differentially expressed.was calculated as the relative content of protein de-
tected. All experiments were performed in three times.
Statistical analysis
Raw fluorescence intensity values were normalized and
log-transformed. Fold change were calculated by Rosetta
Resolver 7.2 with error model adjusted by Amersham
Pairwise Ration Builder for signal comparison of sample.
In bioinformatic analysis, differentially expressed genes
were subjected to hierarchical clustering analysis, prin-
cipal component analysis, Pathway analysis and Gene
Ontology analysis. T-test was applied to analyze differ-
ences of measurement and categorical data. The SPSS
19.0 software (SPSS Inc., Chicago, IL) was used. All data
were expressed as mean ± standard deviation (SD), and
the p value <0.05 was considered statistically significant.
Results
Number of differentially expressed genes
In order to detect the number of genes affected by CXCR7
transfection, we used gene microarray analysis to compare
the fluorescence intensity ratio between the experimental
and control group. Logarithm of fluorescence intensity ra-
tio was represented by Fold change, and log2 ratios ≥ 1.0
or log2 ratios ≤ −1.0 means two Fold change (Figure 1).control groups (O vs N). Fold change represents logarithm of
g2 ratios≥ 1.0 or log2 ratios≤ −1.0 means two Fold change.
control and flagged probes. |Fold change| ≥1 means genes
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expressed genes are as follows: |log2 ratios| ≥ 1 and P <
0.05 (log2 ratios ≥ 1.0 means up-regulated and log2 ra-
tios ≤ −1.0 represents down-regulated) (Figure 2). Our
data indicated CXCR7 transfection up-regulated 529
genes and down-regulated 620 genes.
Hierarchical clustering analysis showed that CXCR7
over-expression modified gene clusters in PTC cells
The correlation of expression profiles between the ex-
perimental and control groups was demonstrated by un-
supervised hierarchical clustering analysis tree (Figure 3).
A subset of differential genes that showed similar proper-
ties was selected for clustering analysis. An intensity filter
was used to select genes where the difference between the
maximum and minimum intensity values exceeds 1200
among all microarrays. For this microarray project, the
number of genes clustered was 270, among which 156
genes were up-regulated and 114 were down-regulated.
Pathway analysis showed that genes regulated by CXCR7
over-expression are mainly involved in KEGG signaling
pathway
By Pathway analysis, We found that differentially ex-
pressed genes were mainly involved in twenty-five KEGG
(Kyoto Encyclopedia of Genes and Genomes) classical
pathway, especially in ECM-receptor interaction (13 genes),Figure 2 Volcano plot of distribution of differentially expressed gene
red and green represent the cut-off, a measurement of gene expression fo
[−Log10 (P-value)] on the Y-axis. Differentially expressed genes are establishFocal adhesion (18 genes), MAPK signaling pathway (20
genes), Cytokine-cytokine receptor interaction (19 genes),
and four BioCarta pathway. Table 2 lists the top 10 signifi-
cant enrichment pathway terms. And Table 3 lists the top
up- and down-regulated genes those were mainly involved
in ECM-receptor interaction pathway, Focal adhesion
pathway, MAPK signaling pathway and Cytokine-cytokine
receptor interaction pathway.Gene ontology analysis results
Gene ontology (GO) database is organized into three
categories describing molecular function (MF), biological
process (BP), and cellular component (CC). To analyze
function differences represented by differentially expressed
genes, we conducted a GO analysis. We found, in MF,
differentially expressed genes significantly enriched in
KINASE_ACTIVITY (29 genes), ION_BINDING (24
genes) and PHOSPHOTRANSFERASE_ACTIVITY_AL
COHOL_GROUP_AS_ACCEPTOR (30 genes); in BP,
the top enrichment terms were SIGNAL_TRANSDUC
TION (89 genes) and energy metabolism process, such
as BIOPOLYMER_METABOLIC_PROCESS (83 genes),
CELLULAR_MACROMOLECULE_METABOLIC_PRO
CESS (68 genes) and PROTEIN_METABOLIC_PRO
CESS (76 genes); in CC, the genes involved in the CY
TOPLASM (113 genes) and cell MEMBRANE_PARTs between the experimental and control groups. The dotted line in
ld-change on the X-axis versus a measure of statistical significance
ed at |Fold change| ≥1 and P-value < 0.05 (Blue dots in Figure 2).
Figure 3 Hierarchical clustering of differentially expressed genes in the experimental and control groups. A hierarchical clustering tree
indicates the gene expression patterns similarity of the 270 genes between the experimental and control groups. The expression levels of the 270
genes are showed by different color lump: red, high (up-regulated); black, medium; and green, low (down-regulated).
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Table 2 The top 10 enrichment pathway terms differentially expressed genes involved in
Pathway name Genes count k/K (%) p value
KEGG_ECM_RECEPTOR_INTERACTION 13 15.48 2.85E-09
KEGG_FOCAL_ADHESION 18 8.96 2.26E-08
KEGG_MAPK_SIGNALING_PATHWAY 20 7.49 7.63E-08
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 19 7.12 3.54E-07
KEGG_GLYCEROPHOSPHOLIPID_METABOLISM 9 11.69 8.70E-06
KEGG_AXON_GUIDANCE 11 8.53 1.93E-05
BIOCARTA_ATRBRCA_PATHWAY 5 23.81 2.70E-05
KEGG_CELL_ADHESION_MOLECULES_CAMS 11 8.21 2.75E-05
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 8 11.59 2.92E-05
KEGG_WNT_SIGNALING_PATHWAY 11 7.28 8.21E-05
Note: Genes count is number of genes involved. k/K is the ratio of k and K, where k = number of genes in the overlap between this pathway genes and
differentially expressed genes, K = total number of genes in the pathway; P value indicates the significance of Genes count.
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of enrichment terms were showed in Table 4.
Verification of differentially expression genes
To partly confirm the expression profiles alteration after
PTC cells transfected with CXCR7 gene, we selected up-
regulated genes of FN1, COL1A1, COL4A1, PDGFRB,
CXCL12, LTB, MMP-11, MT-MMP and down-regulated
genes of ITGA7 and Notch-1 for further verification.
RT-PCR and Western blot analysis revealed that both
mRNA and protein expression levels of genes (FN1,
COL1A1,COL4A1, PDGFRB, CXCL12, LTB, MMP-11,
MT-MMP) were markedly elevated in K1-CXCR7 cells
compared with K1 cells, whereas genes ITGA7 and
Notch-1 were the opposite (Figure 4 and Table 5).
Discussion
In our study, we filtered 270 differentially expressed genes
after PTC cells transfected with CXCR7 cDNA by gene
microarray. Among them, 156 genes were up-regulated
and 144 genes were down-regulated. The best-known ef-
fect of thyroid is an increase in basal energy expenditure
achieved by acting on protein, carbohydrate and lipid
metabolism. As expected, GO enrichment analysis found
several high-enrichment terms linked to metabolism, in-
cluding biopolymer metabolic process (83 genes), cellular
macromolecule metabolic process (68 genes), cellular
protein metabolic process (76 genes) and protein metabolic
process (76 genes). In addition, differentially expressed
genes were significantly involved in signal transduction
biological process (89 genes). Pathway enrichment analysis
found that the most of differentially expressed genes were
enriched in ECM-receptor interaction KEGG pathway (13
genes), focal adhesion KEGG pathway (18 genes), MAPK
signaling KEGG pathway (20 genes) and Cytokine-
cytokine receptor interaction KEGG pathway (19 genes).
Extracellular matrix (ECM) plays an important role in
the development and maintenance of tissue and organarchitecture and homeostasis. The synthesis and degrad-
ation of ECM components (such as type I collagen, type
IV collagen and fibronectin) results in its remodeling and
promotes the activated endothelial cells (ECs) proliferation,
migration and adhesion to ECM, which contributes to
angiogenesis [11].
In this study, fibronectin-1 (FN1) was significantly
up-regulated (log2 (Ratio) =5.5288). It was involved in
ECM-receptor interaction pathway, focal adhesion path-
way, pathways in cancer and regulation of actin cytoskel-
eton pathway. As an important ECM component, FN1
regulates ECs survival, proliferation, adhesion, migration
and angiogenesis [12]. Several researches reported that
FN1 was over-expressed in PTC, and it may be a useful
biomarker to diagnose PTC [13-15]. ECs facilitate tumor
angiogenic process through the activation of focal
adhesion kinase (FAK) and downstream PI3K/Akt sig-
nal pathway, as well as the activation of NF-κB [12,16].
So, we considered that CXCR7 might promote EC
adhesion to ECM by up-regulating the expression of
FN1, inducing FAK-mediated activation of PI3K/Akt
as well as NF-κB pathway, thereby regulating PTC
progression.
COL1A1 (collagen, type I, alpha 1) was also obviously
up-regulated (log2 (Ratio) =4.3820), involved in ECM-
receptor interaction pathway and focal adhesion path-
way in our study, as well as COL4A1 (collagen, type IV,
alpha 1). As is well-known, COL1A1 is expressed in
many tumor cells and tumor-associated stromal cells.
Several researches have demonstrated that COL1A1
plays an important role in angiogenesis and desmoplasia,
and the over-expression of COL1A1 was associated with
invasion process in PTC [17,18]. What’s more, it was
reported that PI3K/AKT and NF-κB pathway were in-
volved in regulating the expression of COL1A1 [19,20].
And COL4A1, as an essential component of ECM, plays
an important role in angiogenesis and tumor progression
[21]. These suggested that PI3K/AKT and NF-κB
Table 3 The top up- and down-regulated genes involved in the significant enrichment pathway
Genes Description log2(Ratio) O/N p value
(Differentially expressed)
KEGG_ECM_RECEPTOR_INTERACTION
FN1 Fibronectin 1 5.5287 0
COL1A1 Collagen, type I, alpha 1 4.3820 0
COL5A1 Collagen, type V, alpha 1 3.2131 9.73E-21
COL4A1 Collagen, type IV, alpha 1 2.0595 5.54465E-06
VWF von Willebrand factor 1.9795 7.64103E-09
LAMA1 Laminin, alpha 1 1.5764 1.77592E-09
TNC Tenascin C (hexabrachion) 1.0455 6.29032E-07
ITGA6 Integrin, alpha 6 −1.1582 0.001988898
LAMA3 Laminin, alpha 3 −1.5196 1.55E-14
ITGA7 Integrin, alpha 7 −1.9969 8.53527E-12
KEGG_FOCAL_ADHESION
FN1 Fibronectin 1 5.5287 0
COL1A1 Collagen, type I, alpha 1 4.3819 0
PDGFRB Platelet-derived growth factor receptor, beta polypeptide 3.7321 1.37E-43
COL5A1 Collagen, type V, alpha 1 3.2131 9.73E-21
SHC2 SHC (Src homology 2 domain containing) transforming protein 2 2.1832 2.58E-15
COL4A1 Collagen, type IV, alpha 1 2.0595 5.545E-06
VWF von Willebrand factor 1.9795 7.641E-09
LAMA3 Laminin, alpha 3 −1.5196 1.55E-14
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 −1.7049 6.82E-27
ITGA7 Integrin, alpha 7 −1.9969 8.535E-12
KEGG_MAPK_SIGNALING_PATHWAY
PDGFRB Platelet-derived growth factor receptor, beta 3.7321 1.37E-43
CD14 CD14 molecule 2.7194 7.86E-15
DUSP1 Dual specificity phosphatase 1 2.0457 2.363E-06
PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) 1.9008 5.062E-07
NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 1.8524 1.126E-11
CACNA1I Calcium channel, voltage-dependent, alpha 1I subunit 1.4363 1.27E-18
ATF4 Activating transcription factor 4 (tax-responsive enhancer element B67) −1.6707 7.347E-05
PRKACB Protein kinase, cAMP-dependent, catalytic, beta −1.7679 2.745E-12
MAP3K4 Mitogen-activated protein kinase kinase kinase 4 −2.1767 0.0014161
NFKB2 Nuclear factor of kappa light polypeptide gene enhancer −2.2731 1.01E-15
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
PDGFRB Platelet-derived growth factor receptor, beta polypeptide 3.7321 1.37E-43
LTB Lymphotoxin beta (TNF superfamily, member 3) 2.9402 1.67E-33
CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 2.7037 5.32E-22
CCL5 Chemokine (C-C motif) ligand 5 2.5225 5.837E-10
CCL21 Chemokine (C-C motif) ligand 21 1.8655 4.374E-07
TNFRSF4 Tumor necrosis factor receptor superfamily, member 4 1.7509 1.69E-15
CXCL2 Chemokine (C-X-C motif) ligand 2 1.4616 3.49E-14
IL23A Interleukin 23, alpha subunit p19 −1.2503 8.442E-08
ACVR2A Activin A receptor, type IIA −1.6469 1.865E-07
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 −1.7049 6.82E-27
Note: log 2(Ratio) O/N is the logarithm of fluorescence intensity ratio of O and N, where O the experimental group (K1 cell transfected with CXCR7), and N is the
control group (K1 cell). |log2 ratios| ≥ 1 and P < 0.05 means the differentially expression genes; P value indicates the significance of log2 (Ratio) O/N.
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Table 4 The top 10 enrichment gene ontology terms
Function category Term Genes count k/K (%) p-Value
Molecular function KINASE_ACTIVITY 29 0.0786 3.03E-11
ION_BINDING 24 0.0879 1.56E-10
TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS 30 0.0708 1.81E-10
CATION_BINDING 19 0.0892 9.88E-09
ENDOPEPTIDASE_ACTIVITY 14 0.1197 2.15E-08
PHOSPHOTRANSFERASE_ACTIVITY_ALCOHOL_GROUP_AS_ACCEPTOR 23 0.0689 3.91E-08
CALCIUM_ION_BINDING 13 0.125 4.04E-08
HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS 20 0.0743 8.62E-08
PEPTIDASE_ACTIVITY 17 0.0909 1.10E-07
PROTEIN_KINASE_ACTIVITY 20 0.0702 2.20E-07
Biological process BIOPOLYMER_METABOLIC_PROCESS 83 0.0493 0.00E?+?00
SIGNAL_TRANSDUCTION 89 0.0545 0.00E?+?00
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS 68 0.0592 0.00E?+?00
CELLULAR_PROTEIN_METABOLIC_PROCESS 68 0.06 0.00E?+?00
PROTEIN_METABOLIC_PROCESS 76 0.0609 0.00E?+?00
SYSTEM_DEVELOPMENT 57 0.0662 0.00E?+?00
MULTICELLULAR_ORGANISMAL_DEVELOPMENT 70 0.0667 0.00E?+?00
ANATOMICAL_STRUCTURE_DEVELOPMENT 71 0.0701 0.00E?+?00
RESPONSE_TO_STRESS 39 0.0768 2.52E-14
ORGAN_DEVELOPMENT 40 0.0701 2.29E-13
Cellular function CYTOPLASM 113 0.0526 0.00E?+?00
MEMBRANE_PART 90 0.0539 0.00E?+?00
INTRINSIC_TO_MEMBRANE 76 0.0564 0.00E?+?00
INTEGRAL_TO_MEMBRANE 76 0.0571 0.00E?+?00
ORGANELLE_PART 69 0.0576 0.00E?+?00
INTRACELLULAR_ORGANELLE_PART 69 0.0579 0.00E?+?00
MEMBRANE 117 0.0587 0.00E?+?00
NUCLEUS 84 0.0587 0.00E?+?00
PLASMA_MEMBRANE 86 0.0603 0.00E?+?00
EXTRACELLULAR_REGION 39 0.0872 3.33E-16
Note: Genes count is number of genes involved. k/K is the ratio of k and K, where k=number of genes in the overlap between this GO term genes and
differentially expressed genes, K=total number of genes in the GO term; P value indicates the significance of Genes count.
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and COL4A1) by CXCR7 in PTC cells.
Chemokines and their receptors are best known for
their ability to mediate the direct migration of leukocytes
in the immune system. As we all known, a close connec-
tion exists between inflammation and cancer. Recently,
accumulating evidence suggests that alterations in im-
mune function may play a crucial role in PTC initiation.
And a history of autoimmune disease, always resulting
in tissue destruction and inflammation, has also been as-
sociated with the increased risk of PTC [22-24]. As shown
in our study, several up-regulated differentially expressed
genes were significantly involved in Cytokine-cytokine
receptor interaction pathway, including PDGFRB (log2
(Ratio) =3.7321), LTB (log2 (Ratio) =2.9402), CXCL12(log2 (Ratio) =2.7037). They are all important pro-
inflammatory molecules, which play important roles in
regulating tumor cells proliferation, invasion, metasta-
sis, angiogenesis and apoptosis. Platelet-derived growth
factors (PDGFs), a family of peptides of growth factors,
bind to their receptors (PDGFR-α and -β) and stimulate
growth and diffusion of cancer cells. It was reported
that PDGFR-α and -β were expressed in PTC but not
found in normal thyroid tissues [25]. And PDGFR-β
can induce the transcription and secretion of vascular
endothelial growth factor (VEGF), which plays a critical
role in tumor growth, angiogenesis and metastasis [26].
LTB, lymphotoxin beta (TNF superfamily, member 3),
is a multifunctional pro-inflammatory cytokine that be-
longs to the tumor necrosis factor (TNF) superfamily.
Figure 4 mRNA and protein expression of differentially expression genes in K1 cell and K1-CXCR7 cell. (A) Relative mRNA expression
level of differentially expression genes (FN1, COL1A1, COL4A1, PDGFRB, LTB, CXCL12, MMP-11, MT1-MMP, ITGA7 and Notch-1). (B) Upper panel:
protein electrophoregram of differentially expression genes. GAPDH protein was used as a loading control. Lower panel: relative protein levels of
differentially expression genes. *p < 0.05.
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multiple biological processes, including cell prolifera-
tion, differentiation and apoptosis. It was reported that
an autocrine inflammatory cytokine network of inflam-
matory cytokine TNF-α, angiogenic factor VEGF, and
chemokine CXCL12 existed in ovarian cancer micro-
environment and stimulated tumor neoangiogenesis [27].
What’s more, TNF-αinduced the production of VEGF and
CXCL12, and VEGF also induced CXCL12 [28,29]. Mean-
while, CXCL12 and VEGF were synergized in facilitating
angiogenesis of ovarian cancer [30]. In addition, anti-
apoptotic and pro-inflammatory abilities of TNF-αwere
resulted from the induction of NF-κB [31,32]. Indeed,
NF-κB is one of the main TNF-α downstream effectors,
and functions as a transcription factor to regulate genes
associated with inflammatory, anti-apoptotic and cellproliferation. Madge LA et al. [33] also demonstrated
that lymphotoxin-beta receptor (LTβR) ligands LIGHT
and LTα1β2 activate NF-κB pathway, and then up-
regulated chemokine CXCL12. CXCL12, also named
stromal cell-derived factor 1 (SDF-1), functions as a chemo-
tactic factor for many cells, including T cells, pre-B-cells,
monocytes, dendritic cells, and hematopoietic progenitor
cells [34,35]. It was also involved in tumor cells migration,
invasion and metastasis [36,37]. What’s important, we
have demonstrated a significantly higher expression level
of SDF-1 in PTC tissue compared with peritumoral non-
malignant tissue and thyroid benign lesion tissue, and the
expression of SDF-1 was closely associated with lymph
node metastasis of PTC [8]. In addition, our research re-
sults suggested that SDF-1 binding to its receptor CXCR7
regulated the directed migration and invasion of PTC
Table 5 Expression of mRNA and protein of genes in K1
cells and K1-CXCR7 cells
Genes CXCR7 mRNA P value CXCR7 protein P value
FN1 0.000 0.000
K1 1.772 ± 0.620 0.240 ± 0.010
K1-CXCR7 12.664 ± 1.080 0.537 ± 0.006
COL1A1 0.000 0.002
K1 3.404 ± 0.617 0.840 ± 0.010
K1-CXCR7 14.150 ± 1.014 1.840 ± 0.046
COL4A1 0.000 0.000
K1 3.146 ± 0.203 0.333 ± 0.045
K1-CXCR7 12.940 ± 1.111 1.026 ± 0.023
PDGFRB 0.000 0.000
K1 4.483 ± 0.552 0.839 ± 0.051
K1-CXCR7 14.441 ± 0.557 1.596 ± 0.019
LTB 0.000 0.010
K1 3.274 ± 0.219 0.270 ± 0.027
K1-CXCR7 8.430 ± 0.112 1.257 ± 0.040
CXCL12 0.000 0.000
K1 3.047 ± 0.276 0.426 ± 0.023
K1-CXCR7 7.014 ± 0.569 0.770 ± 0.009
MMP-11 0.000 0.001
K1 3.674 ± 0.674 0.826 ± 0.057
K1-CXCR7 11.564 ± 1.156 1.304 ± 0.040
MT1-MMP 0.000 0.003
K1 3.842 ± 0.511 1.026 ± 0.059
K1-CXCR7 9. 856 ± 0.960 1.392 ± 0.071
ITGA7 0.000 0.000
K1 5.631 ± 0.413 0.827 ± 0.049
K1-CXCR7 0.741 ± 0.088 0.439 ± 0.018
Notch-1 0.000 0.034
K1 5.818 ± 0.395 1.005 ± 0.073
K1-CXCR7 2.120 ± 0.496 0.789 ± 0.008
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:16 Page 10 of 12cells [9]. So, it is likely that CXCR7 interaction with its
ligand CXCL12, induced expression alterations of pro-
inflammation genes through the induction of NF-κB
signaling, therefore regulated anti-apoptotic and proli-
feration of PTC cells.
Matrix metalloproteinases (MMPs) mediate tumor cell
invasion and metastasis by degrading of ECM. Maeta H
et al. [38] demonstrated that the expression of MMPs
(MMP-2 and MMP-9), as well as their inhibitors (TIMP-1
and TIMP-2) were enhanced in aggressive PTC. Wani N
et al. [39] reported that CXCR7 promoted the metastasis
of breast cancer by up-regulating the activity of MMPs. In
our study, MMP-11 and membrane type 1 matrix metal-
loproteinase (MT1-MMP) were both up-regulated (log2
(Ratio) =1.5055, log2 (Ratio) =1.0861), which demons-
trated that CXCR7 might promote the secretion of MMP-
11 and MT1-MMP by up-regulating genes expression attranscriptional level. Although MMP-11 can’t degrade any
ECM component, it is also associated with tumor progres-
sion and poor prognosis. MMP-11 was found negative in
normal thyroid tissue and thyroid follicular cells but sig-
nificantly expressed in PTC tissues and thyroid carcinoma
cell lines [18,40]. Focal degradation of ECM is the key step
in the invasion of cancer cells, MT1-MMP degrades ECM
by activating proMMP-2, which promote cancer cells
invasion [41]. Nakamura H et al. [42] reported that
MT1-MMP expression was correlated with the activa-
tion of proMMP-2 and lymph node metastasis of PTC,
which suggested expression of proMMP-2 and MT1-
MMP-mediated activation played a vital role in the lymph
node metastasis of PTC. These results indicated that
chemokine receptor CXCR7-induced the transcriptional
activation of MMPs promoted the secretion of MMPs
proteins and resulted in the degradation of ECM, which
induced PTC invasion and lymph node metastasis.
In addition, ITGA7 (integrin, alpha 7), as a cell adhe-
sion molecule, contributes to the interaction between
ECM and cells by binding to its ligand integrin β and is
involved in multiple biological processes, such as human
tissue development, tissue differentiation, and immune
responses. Recently, increasing evidences have demonstra-
ted ITGA7 as a tumor suppressor gene in many human
malignant neoplasms [43-45], including prostate cancer,
liver cancer, glioblastoma multiforme and leiomyosar-
coma. Han YC et al. [44] reported that integrin-link kinase
interaction with miniature chromosome maintenance 7
(MCM7) and MCM7 phosphorylation may be a critical
event in ITGA7 signaling pathway leading to tumor sup-
pression. Tan LZ et al. [45] reported a possible mecha-
nisms of ITGA7-mediated tumor cell growth suppression
is that IGTA7 interacts with tissue inhibitor of metallopro-
teinase 3 (TIMP3), results in the relocation of NF-κB from
nucleus to cytoplasm, and down-regulates cyclin D1.
These processes led to a remarkable suppression of cell
growth. In our study, IGTA7 gene was also significantly
down-regulated (log2 (Ratio) = −1.99689) in K1-CXCR7
cell, which suggested that CXCR7 might promote the
progression of PTC cell by inhibiting the expression of
IGTA7, but functions of ITGA7 in PTC need to be
further studied.
Notch1, as a multifunction transmembrane receptor,
plays a key role in metazoan development. It also
participates in the maintenance of tissue homeostasis by
regulating cell proliferation, differentiation and apoptosis
[46,47]. Notch1 functions as either a tumor suppressor
gene or an oncogene in many human carcinomas, which
is cell type-specific. In thyroid cancers, the role of Notch1
signaling is tumor histological differentiation dependent.
Notch1 signaling was significantly down-regulated in hu-
man anaplastic thyroid carcinoma compared with normal
thyroid cells, over-expression of Notch1 reduced cancer
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ported that Notch1 acted as a tumor suppressor in medul-
lary thyroid carcinoma (MTC), and activation of Notch1
inhibited growth of MTC cells and induced apoptosis of
MTC cells [49-51]. However, Notch1 as an oncogene or
a tumor suppressor gene in PTC remains controversial.
Zhang J et al. [52] showed that Notch1 expression was
higher in PTC compared with normal thyroid tissues,
and higher expression levels of Notch1 was closely as-
sociated with lymphatic metastasis and poor prognosis
of PTC [53,54]. However, Xiao X et al. [55] showed that
Notch1 expression was minimal in papillary and follicular
thyroid cancer cells, and activation of Notch1 inhibited
growth and proliferation of thyroid cancer cells. Our data
indicated that Notch-1 gene was significantly down-
regulated (log2 (Ratio) = −1.3895) in K1-CXCR7 cell, which
suggested Notch-1 gene might have the effect of tumor
suppression in PTC. Several studies have shown that
Notch1 signaling might be involved in regulating tumor
progression through interacting with multiple signaling
pathways, including PI3K/AKT, NF-κB and Wnt pathway
[56-58], but further studies were needed to identify the
functions and mechanisms of Notch1 signaling in PTC.
Other than the genes mentioned above, there are some
genes found to be regulated by CXCR7 in our study but
have few reports on, such as deltex homolog (DTX3),
matrix-remodeling associated 7 (MXRA7). In our study,
expressions of DTX3 and MXRA7 were dramatically in-
creased at transcriptional level (log2 (Ratio) =3.2667,
log2 (Ratio) =2.3092). It was reported that DTX3 may
function as an ubiquitin ligase protein, which regulate the
Notch pathway via some ubiquitin ligase activity [59].
Veiga-Castelli LC et al. [60] demonstrated MXRA7 was
over-expressed in ectopic endometrium, and it may
result in tissue remodeling according to Gene Ontology
analysis. However, the exact functions of these genes are
not clear. Further studies on these genes are needed to
demonstrate their function and correlation with PTC
progression.
Conclusions
In summary, here we demonstrate that CXCR7 mediates
the transcriptional expression of multiple signaling mo-
lecules, including FN1, COL1A1, COL4A1, PDGFRB,
MMP-11, MT1-MMP, LTB, CXCL12, ITGA7 and Notch-1.
These signal molecules are involved in PI3K/AKT, NF-κB,
Notch signal pathway, which may be associated with papil-
lary thyroid carcinoma growth and metastasis. Chemokine
receptor CXCR7 may promote PTC growth and metastasis
via the activation of PI3K/AKT pathway and its down-
stream NF-κB signaling, as well as the down-regulation of
Notch1 signaling. In addition, several genes with unknown
function were found by gene microarray, such as DTX3
and MXRA7, which need to be further studied.Competing interests
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